Experimental drug AR-42 studied in rare brain tumors – early results show promise
NCT ID NCT02282917
First seen Jan 06, 2026 · Last updated Jun 10, 2026 · Updated 21 times
Summary
This early-phase study tested an experimental drug called AR-42 in 7 adults with vestibular schwannoma or meningioma who were already scheduled for tumor removal surgery. The goal was to see if the drug could reach the tumor and affect a specific protein linked to tumor growth. Participants took AR-42 for 3 weeks before surgery, and researchers measured drug levels and protein activity in the removed tumor tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Massachusetts Eye and Ear
Boston, Massachusetts, 02214, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.